MD Conference Express EASD 2012 - (Page Cover1)

Peer-Reviewed DIABETES Clinical Trial Highlights PRESENTS PEER-REVIEWED HIGHLIGHTS OF Translational Research Therapeutic Updates 48th Annual Meeting of the European Association for the Study of Diabetes New ADA/EASD Guidelines Focus on Patient-Centered Care The International Diabetes Federation estimates that up to 1 adult in 10 will have diabetes by 2030 [International Diabetes Federation. IDF Diabetes Atlas. 5th ed. 2009]. To better handle this impending crisis, the latest American Diabetes Association and European Association for the Study of Diabetes guidelines present a new perspective on the management of hyperglycemia in type 2 diabetes. See page 9. Distribution of this independent report is supported by ALSO IN THIS ISSUE • Renal Denervation • Clinical Trial Highlights – The Science Behind Diabetes Treatment • Novel Oral Agents http://www.mdconferencexpress.com http://www.diabetes.org/ http://en.sanofi.com/home.asp

Table of Contents for the Digital Edition of MD Conference Express EASD 2012

MD Conference Express EASD 2012
Contents
Understanding Incretin Hormone Action and the Treatment of Diabetes
New ADA/EASD Guidelines Focus on Patient-Centered Care
ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Fail to Reduce CV Events in Diabetic Patients
Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss Through 4 Years
DiaPep277® Shows Promise as a Therapeutic Strategy for T1DM
Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with T2DM
Insulin Degludec Is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents
Dapagliflozin Does Not Impact Renal Function in Patients with T2DM
Population-Based Screening for T2DM:The ADDITION-Cambridge Trial
The Challenges of Pharmaceutical Management of Painful Diabetic Peripheral Neuropathy
Enterovirus Infection
Novel Oral Agents
GLP-1
Genetics
Renal Denervation
Hypertension and Renal Function Are Risk Factors for CAD in T1DM

MD Conference Express EASD 2012

https://www.nxtbook.com/nxtbooks/md_conference_express/easd2012
https://www.nxtbookmedia.com